PMID: 6967912Oct 1, 1980Paper

Effect of thymopoietin pentapeptide (TP5) on autoimmunity. I. TP5 suppression of induced erythrocyte autoantibodies in C3H mice

The Journal of Immunology : Official Journal of the American Association of Immunologists
C Y LauG Goldstein

Abstract

C3H mice (young and old), when immunized with the cross-reacting rat erythrocytes, produced erythrocyte autoantibodies that usually persisted for more than 10 weeks. I.P. injection of thymopoietin pentapeptide (TP5) once or thrice weekly accelerated the loss of erythrocyte autoantibodies 7 weeks after immunization; 10 ng of TP5 was the optimal dose. The rat agglutinin responses of these immunized mice were unaffected by TP5 during the whole period of study. Spleen cells from rat erythrocyte-immunized mice, when transferred to syngeneic recipients undergoing similar immunization schedules, delayed the appearance of erythrocyte autoantibodies in the recipients. A greater delay was observed when spleen cells were taken from mice that had also received TP5 treatment.

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.